Gruessner A, Sutherland D E
Department of Surgery, University of Minnesota Minneapolis, USA.
Clin Transpl. 1996:47-67.
As of November 1996, more than 8,800 pancreas transplants had been reported to the IPTR. There were 6,500 performed in the US, including more than 5,800 since the inception of the UNOS Registry in October 1987, and more than 1,000 in 1995. In Europe, more than 2,100 cases were reported to the IPTR, while fewer than 200 have been done in other locations. This report analyzes cases reported since 1987. In the US, BD has been used for the majority (92%). However, ED has recently increased in popularity, and for 1995, 15% of US cases were done by this method. In the SPK category results for 1994-1996 BD (n = 1,510) and ED (n = 221) were comparable, with one-year GSRs of 62% and 77%, respectively. When the 1987-1996 US data for BD cases were analyzed according to the 3 major recipient categories, SPK transplants (n = 3,989); PAK transplants (n = 375) and PAK transplants (n = 229), patient survival rates were no different (92%, 92% and 91%, respectively at one year). But one-year pancreas GSRs were significantly higher (p = 0.0001) in the SPK than in the PAK and PTA categories (79%, 60% and 57%, respectively). In the SPK group, the one-year kidney GSR was 88%. Retransplants and primary transplants fared similarly in the SPK category, with one-year GSRs of 79% (n = 3,947) and 77% (n = 42), respectively. But in the PAK category, primary transplants did better, 62% (n = 275) versus 47% (n = 100) functioning at one year. The PTA category outcome was also better for primary than retransplants, with GSRs of 57% (n = 191) and 51% (n = 38) at one year. An improvement in GSRs could be shown over the analyzed time period for all categories; for 1994-1996 cases in the SPK (n = 1,516), PAK (n = 141) and PTA (n = 64) categories, one-year pancreas GSRs were 81%, 71% and 64%, respectively (p = 0.004). The kidney GSR for 1994-96 SPK cases was 88% at one year. Preservation had minimal impact on outcome. In the SPK category, one-year GSRs for pancreases stored less than 12 (n = 1,400), 12-24 (n = 2,256) and more than 24 (n = 195) hours were 78%, 80% and 76%, respectively. The impact of FK506 immunosuppression on pancreas transplant survival was also analyzed for 1994-1996 cases. The results were comparable to those with CsA. For SPK cases, one-year GSRs were 82% with CsA (n = 1,247) and 81% with FK506 (n = 257). The one-year immunological loss rates were 2% and 3%, respectively. For PAK cases, one-year GSRs were 84% for FK506- (n = 42) and 65% for CsA- (n = 97) treated recipients (p < 0.04), and the immunological loss rates at one year were 11% and 7%, respectively. In PTA cases, the one-year GSRs were 66% with CsA (n = 37) and 64% with FK506 (n = 26) with immunological loss rates of 9% and 0%, respectively (p > 0.2). Outcomes were also compared according to whether recipients underwent induction immunotherapy with ALG/ATG/ATS, OKT3, or neither. In the SPK category, GSRs were 81% with OKT3 (n = 1,600), 75% with ALG/ATG/ATS (n = 1,715) and 75% with neither (n = 45) (p < 0.001). In the PAK category, the use of OKT3 (n = 81) was associated with lower graft survival rates than when ALG/ATG/ATS (n = 220) or neither (n = 49) was given (43%, 62%, and 54% at one year, respectively). In the PTA category the use of ALG/ ATG/ATS (n = 132) or OKT3 (n = 76) was associated with significantly higher graft survival (59% and 57%, respectively) than when neither (n = 13) was used (26% at one year). The effect of HLA-A,-B and -DR mismatching on outcome for US cases was determined on both overall graft survival rates and on risks for immunological loss. For SPK cases, the pancreas GSRs were significantly higher (p < 0.04) with zero-mismatched grafts (n = 30) than with higher degrees of mismatches (85% at one year versus 69%, 76% and 79% with one [n = 67], 2-3 [n = 925] and 4-6 [n = 2,836] mismatches, respectively). For PAK cases GSRs were progressively higher with decreasing numbers of mismatches (100%, 75%, 58% and 53% at one year with zero [n = 7], one [n = 35], 2-3 [
截至1996年11月,向国际胰腺移植登记处(IPTR)报告的胰腺移植已超过8800例。美国进行了6500例,其中自1987年10月美国器官共享联合网络(UNOS)登记处成立以来有5800多例,1995年超过1000例。在欧洲,向IPTR报告的病例超过2100例,而在其他地区进行的病例不到200例。本报告分析了自1987年以来报告的病例。在美国,大多数病例(92%)使用的是尸体供胰(BD)。然而,亲属活体供胰(ED)最近越来越受欢迎,在1995年,美国15%的病例采用这种方法。在1994 - 1996年的胰肾联合移植(SPK)类别中,尸体供胰(n = 1510)和亲属活体供胰(n = 221)的结果相当,一年移植物存活率(GSR)分别为62%和77%。当根据三个主要受者类别分析1987 - 1996年美国尸体供胰病例的数据时,即胰肾联合移植(n = 3989)、胰移植(PAK,n = 375)和单独胰腺移植(PTA,n = 229),患者生存率没有差异(一年时分别为92%、92%和91%)。但胰肾联合移植组的一年胰腺移植物存活率显著高于胰移植和单独胰腺移植组(p = 0.0001)(分别为79%、60%和57%)。在胰肾联合移植组中,一年肾移植物存活率为88%。再次移植和初次移植在胰肾联合移植类别中的表现相似,一年移植物存活率分别为79%(n = 3947)和77%(n = 42)。但在胰移植类别中,初次移植效果更好,一年时有功能的比例为62%(n = 275),而再次移植为47%(n = 100)。单独胰腺移植类别中也是初次移植比再次移植效果好,一年移植物存活率分别为57%(n = 191)和51%(n = 38)。在所有类别中,分析时间段内移植物存活率都有提高;对于1994 - 1996年胰肾联合移植(n = 1516)、胰移植(n = 141)和单独胰腺移植(n = 64)类别中的病例,一年胰腺移植物存活率分别为81%、71%和64%(p = 0.004)。1994 - 96年胰肾联合移植病例的一年肾移植物存活率为88%。保存对结果的影响最小。在胰肾联合移植类别中,保存时间少于12小时(n = 1400)、12 - 24小时(n = 2256)和超过24小时(n = 195)的胰腺,一年移植物存活率分别为78%、80%和76%。还分析了1994 - 1996年病例中他克莫司(FK506)免疫抑制对胰腺移植存活的影响。结果与环孢素(CsA)相当。对于胰肾联合移植病例,使用环孢素的一年移植物存活率为82%(n = 1247),使用他克莫司的为81%(n = 257)。一年免疫性失功率分别为2%和3%。对于胰移植病例,使用他克莫司治疗的受者一年移植物存活率为84%(n = 42),使用环孢素的为65%(n = 97)(p < 0.04),一年免疫性失功率分别为11%和7%。在单独胰腺移植病例中,使用环孢素的一年移植物存活率为66%(n = 37),使用他克莫司的为64%(n = 26),免疫性失功率分别为9%和0%(p > 0.2)。还根据受者是否接受抗淋巴细胞球蛋白(ALG)/抗胸腺细胞球蛋白(ATG)/抗胸腺血清(ATS)、OKT3诱导免疫治疗或两者都未接受来比较结果。在胰肾联合移植类别中,使用OKT3的移植物存活率为81%(n = 1600),使用ALG/ATG/ATS的为75%(n = 1715),两者都未使用的为75%(n = 45)(p < 0.001)。在胰移植类别中,使用OKT3(n = 81)与使用ALG/ATG/ATS(n = 220)或两者都未使用(n = 49)相比,移植物存活率较低(一年时分别为43%、62%和54%)。在单独胰腺移植类别中,使用ALG/ATG/ATS(n = 132)或OKT3(n = 76)与两者都未使用(n = 13)相比,移植物存活率显著更高(一年时分别为59%和57%)(一年时为26%)。确定了HLA - A、 - B和 - DR错配对美国病例结果的影响,包括总体移植物存活率和免疫性失功风险。对于胰肾联合移植病例,零错配移植物(n = 30)的胰腺移植物存活率显著高于错配程度更高的移植物(一年时为85%,而错配1个(n = 67)、2 - 3个(n = 925)和4 - 6个(n = 2836)时分别为69%、76%和79%)。对于胰移植病例,随着错配数量减少,移植物存活率逐渐升高(一年时零错配(n = 7)、错配1个(n = 35)、2 - 3个时分别为100%、75%、58%和53%)